Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Express Scripts
Medtronic
Mallinckrodt
Merck

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR ARIPIPRAZOLE LAUROXIL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Aripiprazole Lauroxil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01469039 ↗ A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia Completed Alkermes, Inc. Phase 3 2011-12-01 The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
NCT02320032 ↗ An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia Completed Alkermes, Inc. Phase 1 2014-12-01 This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
NCT02634320 ↗ A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia Completed Alkermes, Inc. Phase 4 2015-12-01 This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
NCT02636842 ↗ A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder Completed Alkermes, Inc. Phase 1 2015-12-01 The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aripiprazole Lauroxil

Condition Name

Condition Name for Aripiprazole Lauroxil
Intervention Trials
Schizophrenia 6
Schizoaffective Disorder 1
Schizoaffective Disorder, Depressive Type 1
Schizophreniform Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aripiprazole Lauroxil
Intervention Trials
Schizophrenia 6
Disease 2
Psychotic Disorders 2
Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aripiprazole Lauroxil

Trials by Country

Trials by Country for Aripiprazole Lauroxil
Location Trials
United States 45
Russian Federation 5
Romania 2
Philippines 2
Ukraine 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aripiprazole Lauroxil
Location Trials
California 6
Illinois 5
Texas 5
Missouri 4
Arkansas 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aripiprazole Lauroxil

Clinical Trial Phase

Clinical Trial Phase for Aripiprazole Lauroxil
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aripiprazole Lauroxil
Clinical Trial Phase Trials
Completed 5
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aripiprazole Lauroxil

Sponsor Name

Sponsor Name for Aripiprazole Lauroxil
Sponsor Trials
Alkermes, Inc. 6
University of California, Los Angeles 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aripiprazole Lauroxil
Sponsor Trials
Industry 6
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
Express Scripts
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.